1.888.321.7828 sales@pepid.com

Timely Insights for Healthcare Experts 

Stop Using Aspirin For Routine Primary Prevention of ASCVD

Low-dose aspirin has been recommended and used for decades for prevention of ASCVD. It is well established for SECONDARY prevention of ASCVD, however, recent studies have shown aspirin should not be used for routine PRIMARY prevention of ASCVD due to lack of benefit....

read more
FDA Approves New Treatment for HSDD in Premenopausal Women

FDA approves bremelanotide  (Vyleesi, AMAG Pharmaceuticals) to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Bremelanotide is the first-in-class melanocortin 4 receptor agonist for HSDD, and joins Flibanserin as...

read more
First P13K inhibitor for Breast Cancer Gets FDA Approved

Pigray (alpelisib) tablets have been FDA approved to treat breast cancer in combination with FDA-approved endocrine therapy fulvestrant. Pigray is approved for postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2...

read more
Novel FDA Drug Approvals: February-May 2019

Every year, the US FDA’s Center for Drug Evaluation and Research (CDER) releases a list of newly-approved novel drugs and therapeutic biological products. Last year's Novel Drug Approvals list holds the record for the most number of approved drugs, effectively...

read more
Breakthrough Non-Drug ADHD Treatment Gets FDA Approval

Children living with attention hyperactivity disorder (ADHD) may soon experience non-pharmacologic relief through a breakthrough medical device. For children between the ages 7 and 12 and currently not on medication, the pocket-sized device works by delivering mild...

read more
CDC Update: E. Coli O103 Outbreak Is from Ground Beef

Update to PEPID Pulse “E. Coli O103 Outbreak Investigation in Five States” on April 5 , 2019 The CDC has narrowed the Shiga Toxin-producing Escherichia Coli (E. Coli) O103 outbreak to ground beef.  The total number of people infected has increased to 109 people...

read more